Strong CD8+lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy

Author(s):
Groot, A.F. de (0000-0001-7612-2918); Blok, E.J.; Charehbili, A.; Engels, C.C.; Smit, V.T.H.B.M.; Dekker-Ensink, N.G.; Putter, H.; Kranenbarg, E.M.K.; Velde, C.J.H. van de (0000-0003-0104-1800); Liefers, G.J.; Nortier, J.W.R.; Kuppen, P.J.K. (0000-0002-0294-3251); Burg, S.H. van der (0000-0002-6556-0354); Kroep, J.R.
Published
2019
Publication type
Article / Letter to editor
Neoadjuvant chemotherapyBreast cancerZoledronic acidTumor-infiltrating lymphocytesHLA class 1Pathological complete response
Date issued
2019-06-30
Language
English
Is part of
Breast Cancer Research and Treatment (2019), Vol. 175, no. 3, p. 605-615
hdl
1887/121312
doi
10.1007/s10549-019-05195-y